Prime Medicine Receives New Zealand CTA Clearance for PM577a in Wilson Disease
CAMBRIDGE, Mass., June 18, 2026 Prime Medicine, Inc. announced that New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe)...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
CAMBRIDGE, Mass., June 18, 2026 Prime Medicine, Inc. announced that New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe)...
LONDON — November 26, 2025. Tangram Therapeutics has submitted a Clinical Trial Application (CTA) to the UK Medicines and...
